Overview

Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Prospective, open-label, two-way crossover, phase Ib drug-drug interaction study in patients with advanced solid tumors
Phase:
Phase 1
Details
Lead Sponsor:
PharmaMar
Treatments:
Itraconazole